Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8
- PMID: 35319989
- PMCID: PMC8942354
- DOI: 10.1126/sciadv.abh4050
Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8
Abstract
Radiotherapy is a mainstay cancer therapy whose antitumor effects partially depend on T cell responses. However, the role of Natural Killer (NK) cells in radiotherapy remains unclear. Here, using a reverse translational approach, we show a central role of NK cells in the radiation-induced immune response involving a CXCL8/IL-8-dependent mechanism. In a randomized controlled pancreatic cancer trial, CXCL8 increased under radiotherapy, and NK cell positively correlated with prolonged overall survival. Accordingly, NK cells preferentially infiltrated irradiated pancreatic tumors and exhibited CD56dim-like cytotoxic transcriptomic states. In experimental models, NF-κB and mTOR orchestrated radiation-induced CXCL8 secretion from tumor cells with senescence features causing directional migration of CD56dim NK cells, thus linking senescence-associated CXCL8 release to innate immune surveillance of human tumors. Moreover, combined high-dose radiotherapy and adoptive NK cell transfer improved tumor control over monotherapies in xenografted mice, suggesting NK cells combined with radiotherapy as a rational cancer treatment strategy.
Figures







Similar articles
-
CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α.Front Immunol. 2019 Jan 29;10:14. doi: 10.3389/fimmu.2019.00014. eCollection 2019. Front Immunol. 2019. PMID: 30761123 Free PMC article.
-
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.J Immunother Cancer. 2020 May;8(1):e000450. doi: 10.1136/jitc-2019-000450. J Immunother Cancer. 2020. PMID: 32439799 Free PMC article.
-
Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor.Blood. 2012 Apr 26;119(17):3987-96. doi: 10.1182/blood-2011-09-379693. Epub 2012 Mar 7. Blood. 2012. PMID: 22403260
-
Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.Stem Cells Transl Med. 2020 Sep;9(9):974-984. doi: 10.1002/sctm.19-0423. Epub 2020 May 16. Stem Cells Transl Med. 2020. PMID: 32416056 Free PMC article. Review.
-
The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.Hum Immunol. 2015 May;76(5):385-91. doi: 10.1016/j.humimm.2014.09.021. Epub 2014 Oct 8. Hum Immunol. 2015. PMID: 25305457 Review.
Cited by
-
Innate Immune System in the Context of Radiation Therapy for Cancer.Cancers (Basel). 2023 Aug 4;15(15):3972. doi: 10.3390/cancers15153972. Cancers (Basel). 2023. PMID: 37568788 Free PMC article. Review.
-
The current understanding of the immune landscape relative to radiotherapy across tumor types.Front Immunol. 2023 Mar 16;14:1148692. doi: 10.3389/fimmu.2023.1148692. eCollection 2023. Front Immunol. 2023. PMID: 37006319 Free PMC article. Review.
-
The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies.Front Immunol. 2025 Jan 14;15:1440830. doi: 10.3389/fimmu.2024.1440830. eCollection 2024. Front Immunol. 2025. PMID: 39877377 Free PMC article. Review.
-
Natural killer cell therapies.Nature. 2024 Feb;626(8000):727-736. doi: 10.1038/s41586-023-06945-1. Epub 2024 Feb 21. Nature. 2024. PMID: 38383621 Review.
-
Mechanistic rationales for combining immunotherapy with radiotherapy.Front Immunol. 2023 Jun 12;14:1125905. doi: 10.3389/fimmu.2023.1125905. eCollection 2023. Front Immunol. 2023. PMID: 37377970 Free PMC article. Review.
References
-
- Bonner J. A., Harari P. M., Giralt J., Azarnia N., Shin D. M., Cohen R. B., Jones C. U., Sur R., Raben D., Jassem J., Ove R., Kies M. S., Baselga J., Youssoufian H., Amellal N., Rowinsky E. K., Ang K. K., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567–578 (2006). - PubMed
-
- Klug F., Prakash H., Huber P. E., Seibel T., Bender N., Halama N., Pfirschke C., Voss R. H., Timke C., Umansky L., Klapproth K., Schäkel K., Garbi N., Jäger D., Weitz J., Schmitz-Winnenthal H., Hämmerling G. J., Beckhove P., Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589–602 (2013). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous